ライフサイエンスコーパス: elimination half-life

1 dose-dependent increases in C(max), AUC, and elimination half-life.

2 ine appear to be well explained by the brain elimination half-life.

3 O(6)-BG rapidly disappeared from plasma (elimination half-life = 0.54 +/- 0.14 hours) and was con

4 e as follows: volume of distribution, 126 L; elimination half-life, 13.8 hrs; and clearance, 109 mL/m

5 inetic profile of ISIS 3521 revealed a short elimination half-life (18 to 92 minutes), as well as a d

6 under dynamic conditions (dosing every 12h; elimination half-life: 1h).

7 icrog/mL; clearance rate, 6.33 +/- 6.41 L/h; elimination half-life, 24.4 +/- 14.6 hours; volume of di

8 ur) and a relatively slow elimination phase (elimination half-life, 27 hours).

9 s good oral bioavailability (47%) and plasma elimination half-life (3 h) in rats, compound 3 offers a

10 to a longer-lived metabolite, 8-oxo-O(6)-BG (elimination half-life = 5.6 +/- 2.7 hours) and further t

11 okinetic variable estimates were as follows: elimination half-life, 5.16 hrs (1.83 hrs); volume of di

12 Both radiotracers underwent fast systemic elimination (half-life, 8-15 min) through the kidneys, w

13 Although there was a long elimination half-life, accumulation of penclomedine over

14 armacokinetic profile in rats, with a plasma elimination half-life after intravenous dosing of 4.5 h,

15 Its elimination half-life allows dosing twice per day, and a

16 ions of brain fluoxetine bioavailability and elimination half-life also were similar between age grou

17 systemic exposure of drugs that have a short elimination half-life and are given by intermittent intr

18 mean maximum plasma concentration (C max ), elimination half-life and area under concentration-time

19 ent on our preference for drugs with a short elimination half-life and discuss some therapeutic choic

20 gregation) state, CCR-5 specificity, in vivo elimination half-life, and anti-HIV activity of CCL-5-ba

21 NTERPRETATION: The good safety profile, long elimination half-life, and antimalarial effect of DSM265

22 The terminal elimination rate, elimination half-life, area under the curve, maximum pla

23 converted to SU0020, which exhibited a long elimination half-life averaging 19 +/- 12 days.

24 me (tmax) between 1.5 h and 4 h, with a mean elimination half-life between 86 h and 118 h.

25 of a drug such as diclofenac acid, vitreous elimination half-life can be prolonged up to 24 days, po

26 l elimination half-life)primate << (terminal elimination half-life)dog; and (mean residence time)prim

27 characteristics of benzodiazepine use (e.g., elimination half-life, dosage, duration of use) are most

28 alysis of blood clearance studies showed the elimination half-life for [sc(Fv)2]2, sc(Fv)2, and IgG a

29 The brain elimination half-life for fluorinated psychotropic compo

30 The modeled elimination half-life for men is 4.7 years, and the mode

31 f-life for men is 4.7 years, and the modeled elimination half-life for women when excluding losses fr

32 The elimination half-life for women when menstruation is inc

33 The whole body, total elimination half-life (HLT) and the whole body, primary

34 We calculated the apparent elimination half-life in each individual for each dioxin

35 The drug was stable in vivo with a plasma elimination half-life in mice of 405 minutes after i.p.

36 absorption of MGCD0103 within 1 hour and an elimination half-life in plasma of 9 (+/- 2) hours.

37 w clearance from 0.2 to 0.6 L/d/m(2), and an elimination half-life in the range of 3 to 7 days.

38 and 1.6-fold respectively, and the terminal elimination half-life increased 20-fold.

39 lative to those in control rats, whereas the elimination half-life increased significantly.

40 So would the use of an agent whose elimination half-life is so long as to render in-hospita

41 njection of PEG-Cp40 resulted in a prolonged elimination half-life of >5 days but may potentially aff

42 Blood clearance studies showed the elimination half-life of (99m)Tc-labeled sc(Fv)(2) as 14

43 om the lungs fit a first order model with an elimination half-life of 10.5+/-0.9h (R(2)=0.995) and 10

44 In mice, annexin A5-CCPM displayed a mean elimination half-life of 12.5 h.

45 Mean Tmax was 2-4 hours with elimination half-life of 15-20 hours.

46 ime curve, while the agent exhibited a rapid elimination half-life of 2 to 10 minutes.

47 An estimated average intrinsic elimination half-life of 2.4 years (1.8-3.1 years accoun

48 bed after SC administration (89%) and had an elimination half-life of 23 minutes.

49 ith an absorption half-life of 0.81 h and an elimination half-life of 28.76 h, respectively.

50 The drug was cleared, with an elimination half-life of 4 h and a terminal half-life of

51 s C(max) = 1 hour, bioavailability of 8.84%, elimination half-life of 4 hours, and an enterohepatic r

52 te is comparable to the geometric mean serum elimination half-life of 4.8 years reported in individua

53 During treatment, methanol had an elimination half-life of 54 hours.

54 g concentrations, and had a similar terminal elimination half-life of 7-8 h.

55 for the satiety threshold and the functional elimination half-life of cocaine of approximately 1.7 mg

56 eters: the dose of cocaine administered, the elimination half-life of cocaine, and an amount of cocai

57 The elimination half-life of CTpr levels ranged from 26.9 to

58 The elimination half-life of diclofenac suspension was 24 an

59 The elimination half-life of fluvoxamine was found to be sub

60 a, as well as significant differences in the elimination half-life of interstitial fluid Abeta measur

61 ses of atracurium infusion and the increased elimination half-life of laudanosine, only moderate accu

62 The estimated plasma elimination half-life of Marimastat was 4 to 5 hours.

63 The elimination half-life of plasma total anthocyanins was c

64 Based on activity data, the elimination half-life of rFIX was 18.9 +/- 2.3 hours and

65 Further, the elimination half-life of the drug in the vitreous was as

66 the time-concentration curve)dog; (terminal elimination half-life)primate << (terminal elimination h

67 lasma concentration of 36.4 microM (terminal elimination half-life range, 447 to 1176 hours), steady-

68 ation with telaprevir increased the terminal elimination half-life (t((1/2))) of cyclosporine from a

69 concentration (c(max)) of 56.1 mug/mL and an elimination half-life (t(1/2)) of 7.19 days with a coeff

70 of distribution/bioavailability (Vd/F), and elimination half-life (t(1/2)) were not different betwee

71 , 32% to 88%) with a 51% prolongation of the elimination half-life (t(1/2); 90% CI, 32% to 74%).

72 on, EA remained in the plasma longer with an elimination half-life t1/2E at 1.36+/-0.59 versus 1.06+/

73 .0 L/m2, clearance 0.49 +/- 0.18 L/h/m2, and elimination half-life (t1/2) 12.3 +/- 3.8 hours.

74 CPT-11 exhibited a mean elimination half-life (t1/2) of 8.8 hours, an average cl

75 VITREOUS ELIMINATION HALF-LIFE (T1/2) WAS CALCULATED TO BE 9 DAYS

76 (T1/2el = 0.90 h), mavacoxib has a prolonged elimination half-life (T1/2el = 135 h) following oral ad

77 The mean ratio of fluvoxamine brain elimination half-life to plasma half-life was 2.4.

78 The mean (+/- SD) clearance and terminal elimination half-life values for cantuzumab mertansine a

79 was dose-linear and the mean terminal-phase elimination half-life values ranged from 3.1 to 6.3 days

80 Elimination half-life values were short (range, 0.01 to

81 The estimated median elimination half-life was 1.6 days (range, 0.9 to 4.0 da

82 were dose proportional and the mean terminal elimination half-life was 36.4 h (range 32.8-46.0).

83 The elimination half-life was 4.47 +/- 0.53 hours for 9-AC l

84 NNAL and NNAL-Gluc was 3-4 days, whereas the elimination half-life was 40-45 days.

85 The estimated elimination half-life was 46-62 h.

86 The mean apparent elimination half-life was approximately 2 hours, and mea

87 tions of lanadelumab were observed; the mean elimination half-life was approximately 2 weeks.

88 The terminal elimination half-life was approximately 24 hours, and st

89 The laudanosine elimination half-life was calculated.

90 A short elimination half-life was identified, which suggests tha

91 uced (8.21 mL/h vs 12.68 mL/h; P = .003) and elimination half-life was prolonged in women compared wi

92 Laudanosine elimination half-life was prolonged to 617 mins, which w

93 Elimination half-life was short in volunteers with proph

94 Alprazolam elimination half-life was shortened from a mean (SD) of

95 F-I concentrations were reached earlier, the elimination half-life was shorter, clearance was more ra

96 ted steady-state volume of distribution, and elimination half-life were 3.7 L/h, 10.6 L, and 3.7 hour

97 f distribution at steady-state, and terminal elimination half-life were 7.7 ng/mL, 47.7 L/h, 1,763 L,

98 , total volume of distribution, and terminal elimination half-life were approximately 3 L/h, 40 L, an

99 to reach maximum concentration and terminal elimination half-life were not significantly different b

100 enhancement [Emax], time to peak [Tmax], and elimination half-life) were measured on enhancement-vers

101 ature of ropeginterferon alfa-2b is a longer elimination half-life, which allows administration every